B7981080

A phase 3 randomized, double-blind, 52-week placebocontrolled multi-center study with a double-blind 52-week extension period with randomized dose up/dose down titration investigating the efficacy, safety, and tolerability of Ritlecitinib in adult participants with nonsegmental vitiligo.

Register Today!

Trial Information

Start DateJune 2024
End Date~ June 2025
Number of Visits10
StatusOngoing

For additional information
on this trial contact:

Phone(705) 566-0005